Abstract Aim: Chronic ischaemic cardiovascular disease (CICD) remains a leading cause of morbidity and mortality worldwide. The CICD Pilot Registry enrolled 2420 patients across 10 European Society of Cardiology countries prospectively to describe characteristics, management strategies and clinical outcomes in this setting. We report here the six-month outcomes. Methods and results: From the overall population, 2203 patients were analysed at six months. Fifty-eight patients (2.6%) died after inclusion; 522 patients (23.7%) experienced all-cause hospitalisation or death. The rate of prescription of angiotensin-converting enzyme inhibitors, beta-blockers and aspirin was mildly decreased at six months (all P < 0.02). Patients who experienced all-cause hospitalisation or death were older, more often had a history of non-ST-segment elevation myocardial infarction, of chronic kidney disease, peripheral revascularisation and/or chronic obstructive pulmonary disease than those without events. Independent predictors of all-cause mortality/hospitalisation were age (hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.07-1.27) per 10 years, and a history of previous peripheral revascularisation (HR 1.45, 95% CI 1.03-2.03), chronic kidney disease (HR 1.31, 95% CI 1.0-1.68) or chronic obstructive pulmonary disease (HR 1.42, 95% CI 1.06-1.91, all P < 0.05). We observed a higher rate of events in eastern, western and northern countries compared to southern countries and in cohort 1. Conclusion: In this contemporary European registry of CICD patients, the rate of severe clinical outcomes at six months was high and was influenced by age, heart rate and comorbidities. The medical management of this condition remains suboptimal, emphasising the need for larger registries with long-term follow-up. Ad-hoc programmes aimed at implementing guidelines adherence and follow-up procedures are necessary, in order to improve quality of care and patient outcomes.
Introduction
Despite major progress in the diagnosis and treatment of patients with chronic ischaemic cardiovascular disease (CICD), this condition remains one of the leading causes of mortality and morbidity worldwide. [1] [2] [3] Several explanations, including the aging of the population, the rise in the prevalence of comorbidities and the difficulties associated with access to medical care have been put forward to explain the difference between the expected benefit and real-life morbidity and mortality. The new diagnostic tools, increased awareness of preventive measures and the wide dissemination of revascularisation procedures appear insufficient to reverse the poor outcomes. Moreover, contemporary data are lacking, especially in Europe, properly to evaluate the prognosis of these patients. The purpose of the Chronic Ischaemic Cardiovascular Disease Registry, developed by the European Society of Cardiology (ESC) under the EURObservational Research Programme (EORP), was to collect contemporary data on demographic characteristics, clinical profiles, management and clinical outcomes in CICD patients across ESC countries. The CICD Pilot Registry was performed in 10 participating countries and the baseline characteristics and treatment modalities were previously reported. 4 The aim of this study was to report the six-month follow-up and the clinical outcomes of this cohort.
Methods

Study design
The CICD Pilot Survey is an international, prospective, observational and longitudinal registry of patients with a broad spectrum of CICD. The study has been approved by local institutional review boards and all patients gave informed consent in accordance with national and local regulations. Patients were recruited in 100 centres from 10 countries: two western (France, Germany, 20 centres, n ¼ 405 patients), two northern (Latvia, Lithuania, six centres, n ¼ 404 patients), three eastern (Poland, Romania, Russia, 45 centres, n ¼ 1025 patients), and three southern countries (Greece, Italy, Portugal, 29 centres, n ¼ 586 patients). The national cardiac societies of each participating country agreed to participate in the programme and were asked to select centres that were able to recruit consecutive patients in the following cohorts: cohort 1: patients with chronic coronary artery disease (CAD) and non-ST elevation acute coronary syndrome (ACS) undergoing a percutaneous coronary intervention (PCI) within 72 hours from symptom onset, enrolled in the catheterisation laboratory (ACS-PCI group); cohort 2: patients with chronic stable CAD undergoing elective coronary intervention enrolled in the catheterisation laboratory (elective PCI group); cohort 3: stable CAD patients enrolled in general hospitals, clinics without interventional and cardiovascular surgery facilities (stable CAD group); and cohort 4: patients with peripheral artery disease interventions (PAD group). The centre selection and monitoring modalities were published previously. 5 
Organisation
The study was conducted by an independent executive committee (Supplementary Appendix 1) responsible for the formulation and implementation of the study protocol. A steering committee composed of the chairperson of the executive committee and of each national coordinator was created, in order to ensure national feedback on the protocol and proper implementation of the survey at the national level. The EORP department of the ESC was appointed to: (a) coordinate the project and the operations of the CICD Pilot; (b) provide support to the committees, national coordinators and participating centres; (c) ensure quality control of data and study procedure. A signed informed consent was obtained. The database was set up at the European Heart House, according to the requirements defined by the executive committee, and the statistical analyses were performed by the EORP department.
Outcomes
The following outcomes were assessed at six months: all-cause death, cardiovascular and non-cardiovascular death, all causes of rehospitalisation, cardiovascular, CAD related and non-cardiovascular rehospitalisation. The primary outcome was the composite endpoint of all-cause death or all-cause rehospitalisation. Classification of the endpoints was made by the investigators. All deaths were considered cardiovascular unless an unequivocal non-cardiovascular cause could be established. All events were recorded in the e-CRF.
Statistical analysis
Univariate analysis was applied to both continuous and categorical variables. Continuous variables were reported as mean AE SD and/or as median and interquartile range (IQR). Between-group comparisons were made using a non-parametric test (KruskalWallis test). For the comparisons of repeated measures, the paired t-test was used. Categorical variables were reported as percentages (without missing values, if applicable). Between-group comparisons were made using a chi-square test or a Fisher's exact test if any expected cell count was less than five. For qualitative variables with more than two possibilities, the Monte Carlo estimates of the exact P values were used. For the comparisons of repeated measures, the Bowker's test was used. Plots of the Kaplan-Meier curves for both all causes of death and/or all causes of rehospitalisation and cardiovascular deaths and/or cardiovascular rehospitalisations were performed.
A stepwise multiple Cox regression was used to determine the predictors of all causes of death or all causes of rehospitalisation, cardiovascular disease deaths or cardiovascular rehospitalidations and all causes of death including in the model all the candidate variables (variables with P < 0.10 in univariate). A significance level of 0.05 is required to allow a variable into the model (SLENTRY ¼ 0.05) and a significance level of 0.05 is required for a variable to stay in the model (SLSTAY ¼ 0.05). Among variables selected in the multivariate models, interaction was tested with region and cohort. No interaction was significant at 0.05. A Hosmer and Lemeshow goodness of fit test was used to verify that the model was optimal.
A two-sided P value of less than 0.05 was considered statistically significant. All analyses were performed using SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
From the original cohort of 2420 patients included in the registry, three died before discharge and 217 were lost to follow-up or had an unknown status at six months ( Figure 1) . Therefore, follow-up data were available for 2200 patients. The mean follow-up duration was 7.2 AE 2.9 months. Table 1 describes the baseline characteristics of the whole follow-up cohort and across the four regions and by cohort ( Table 2 ). Mean age was 66.6 years and two thirds of the patients were men. The vast majority of these patients had hypertension or hypercholesterolaemia, 28.9% had diabetes mellitus, 60.4% had a previous revascularisation and 25.3% a previous ST-segment elevation myocardial infarction (STEMI). Supplementary material 1 shows drug treatment at discharge and at six months among survivors. There was a mild but significant decrease in the rate of prescription of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and antiplatelet agents.
After inclusion, 58 patients (2.6%) died in hospital/ during follow-up and the majority of fatal events was cardiovascular. A total of 490 patients (22.5%) were hospitalised for any cause, mostly for cardiovascular causes (n ¼ 401, 18.4%). The composite of all-cause death or all-cause rehospitalisation occurred in 23.7% of the patients and the composite of cardiovascular death or cardiovascular hospitalisation occurred in 19.5%. Figure 2 shows the Kaplan-Meier curve for all-cause death or hospitalisation and cardiovascular death or hospitalisation.
The incidence of the primary outcome and of the composite of cardiovascular death or hospitalisation was higher in cohorts 1 and 4 (28.0% and 29.6%, respectively, for the primary outcome; 23.7% and 22.2% for cardiovascular death/hospitalisation) than in cohorts 2 and 3 (Table 3) .
Patients who died or were rehospitalised were older, more likely to be in cohorts 1 or 4, had a higher baseline heart rate and were more likely to have a history of previous non-STEMI, peripheral revascularisation, chronic kidney disease or chronic obstructive pulmonary disease (COPD) (see Supplementary material 2 and 3). Tables 4, 5 and 6 summarise the predicting factors of all-cause death or all-cause rehospitalisation (Table 4) , cardiovascular death/cardiovascular hospitalisations (Table 5 ) and all-cause death (Table 6 ) with the results of both univariate and multivariate Cox analyses.
The independent predictors of all-cause death/ all-cause hospitalisation were age (hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.07-1.27) per 10 years, a history of previous peripheral revascularisation (HR 1.45, 95% CI 1.03-2.03), of chronic kidney disease (HR 1.31, 95% CI 1.03-1.68) or COPD (HR 1.42, 95% CI 1.06-1.91) and cohort 1 (all P < 0.05) ( Figure 3) .
Similarly, independent predictors of cardiovascular death or hospitalisation were COPD (HR 1.45, 95% CI 1.03-2.03) and cohorts 1 and 4. For all-cause deaths, independent predictors were age, a history of chronic kidney disease and region. However, the goodness of fit was low due to the limited number of events.
Finally, we observed a higher rate of events in eastern, western and northern countries compared to southern countries.
Discussion
The six-month follow-up of this European contemporary registry of patients with a broad spectrum of CICD demonstrates several findings: first, the rate of prescription of important recommended drugs declined at six months. Second, the rate of clinical events, mainly driven by cardiovascular events, was very high. Third, there was an important variation in the event rate between cohorts and geographical origin, PAD patients having the worst prognosis.
Medical treatment
At baseline, the rate of prescription of drugs used in secondary prevention was similar to or higher than in other contemporary or recent registries, particularly regarding the use of renin-angiotensin system inhibitors, beta-blockers or aspirin. [5] [6] [7] This may be partly due to the fact that we included non-STEMI patients who were treated intensively during the acute phase. However, we observed a decrease in the rate of prescription of ACE inhibitors or angiotensin receptor blockers, beta-blockers and aspirin at six months in all the cohorts. Although the benefit of ACE inhibitors or beta-blockers on clinical outcomes has recently been questioned in stable CAD without heart failure and outside post-myocardial infarction, there is a general trend for a mild reduction in the prescription of secondary preventive therapies in this very high cardiovascular risk population. 8, 9 The reasons could include a suboptimal cooperation between inhospital and downstream healthcare professionals, cost of medication issues, access to healthcare and insufficient patient education. However, we did not observe any reduction in the rate of prescription of statins, which have demonstrated a protective effect on cardiovascular events, not only in randomised clinical trials but also in a large registry of stable CAD patients.
8,10
Event rate
We observed a high rate of clinical events during this middle-term period of follow-up: 2.6% of our patients died of any cause, nearly one in four either died or was rehospitalised and approximately three-quarters of events were cardiovascular. These results are in line with other contemporary observational studies: in the REACH registry, the rate of all-cause mortality was 2.8% per annum in the subgroup of patients with established CVD and the annual rate of cardiovascular death, myocardial infarction, stroke or hospitalisation for atherothrombotic events was 15%. 5 Similarly, the two-year rate of all-cause death was 2.6-3.5% based on the presence or absence of angina/ischaemia in the CLARIFY registry, which enrolled patients with stable CAD. 8 Our observation therefore confirms that a European population with a broad spectrum of chronic ischaemic heart disease is at very high cardiovascular risk and should be carefully followed up.
Cohort and geographical variations
We observed important variations in the event rate across the four cohorts of patients and the four geographical regions: the primary endpoint occurred more frequently in PAD or non-STEMI (cohorts 1 and 4) patients than in stable CAD patients (cohorts 2 and 3).
Patients with an acute coronary event such as non-STEMI are exposed to myocardial damage and acute complications: stent thrombosis, rhythm disorders, renal failure and bleeding, leading to a higher mortality compared to stable patients. 11, 12 As reported here, a particularly high cardiovascular risk of patients with PAD was observed in the REACH registry:
5 one-year all-cause mortality was 3.8% compared to 2.6% in the overall population and the rate of cardiovascular death, myocardial infarction, stroke or atherothrombotic events reached 21%. Patients with polyvascular disease were in particular at very high risk. Several explanations can be put forward to explain the high rate of events in this subgroup: lack of physician awareness, perception that the global cardiovascular risk associated with PAD is lower than that associated with cardiac disease, and the frequency of multiple vascular localisations. Our observation emphasises the need for increased awareness among physicians and patients of the existence of silent multiple vascular localisations of atherosclerosis and the value of extensive evaluation of the cardiovascular system in these patients. We also observed an important variation in the event rate in the different European regions: events were almost twice as frequent in the western region as in the southern countries, and the incidence of clinical outcomes was also higher in eastern and northern countries. Important geographical variations have previously been reported: in the REACH registry the event rate was particularly high in Eastern Europe, Latin America and in the Middle East and was low in Japan. 13 Access to medical care as well as geographical variations in the prevalence and control of major cardiovascular risk factors can explain these differences: in the CLARIFY registry it was observed that raised lowdensity lipoprotein varied from 24% to 65%, diabetes from 16% to 60%, raised blood pressure from 28% to 48% across different regions worldwide, and that rates of risk factor control also varied considerably. 14 
Predictors of outcomes
We identified a number of clinical factors associated with the occurrence of the primary composite endpoint by univariate analysis. The multivariate Cox analysis showed that a few independent clinical factors were predictive of the primary outcome: age, region, cohort 1, previous peripheral revascularisation, chronic kidney disease and COPD. Similarly, cohorts 1 and 4, region and COPD independently predicted cardiovascular death or cardiovascular hospitalisation.
Interestingly, traditional risk factors such as smoking and hypercholesterolaemia were not independent predictors of events in our cohort. This holds true in particular for diabetes mellitus, which was a strong predictor of all-cause and cardiovascular death in the REACH registry. 15 This difference may be related to the fact that the prevalence of diabetes mellitus was lower in our study.
Limitations
Selection of centres was made on a voluntary basis and we cannot exclude a centre bias regarding the clinical profile and the treatment of patients enrolled. Important heterogeneity exists by design between the different cohorts of patients included in our registry, due to different inclusion criteria, but the registry tried to capture all aspects of CICD except stroke and STEMI. The limited size of this pilot phase makes analysis of geographical variations difficult. These geographical variations will be better captured in the long-term registry which targets a total of 15,000 patients across ESC countries. Outcomes were recorded by investigator report. Therefore, we cannot exclude some variation among investigators regarding assessment of cardiovascular death or hospitalisation, although guidance was provided. Eight per cent of our patients were lost to follow-up or had an unknown status during the follow-up period. This finding documents the fact that follow-up procedures of patients with CICD are still suboptimal, but we believe that this did not impact on our overall interpretation of the results. Another limitation is the fact that the inclusion rate in the different cohorts was variable across the four regions, therefore potentially influencing outcomes. Finally, quality control was performed by queries following coherence of data check and there was no systematic random auditing of the data.
Conclusion
In this contemporary European registry with CICD patients, the rate of clinical events at six months is high, variable across regions and influenced by age and comorbidities. The medical management of this condition remains suboptimal, and emphasises the need to conduct a larger registry with long-term follow-up to evaluate clinical practice in Europe and improve the management of CICD patients. Specific programmes to improve adherence to guidelines and follow-up procedures should be promoted by scientific societies and/or healthcare systems.
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